B R U A RY 28, 2022 On Target to Outsmart Cancer TM © 2022 Revolution Medicines Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain existing collaborations, inclu ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Peg Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Executive Officer Steve Kelsey - President of R&D Jack Anders - Senior Vice President, Finance and Principal Accounting Officer Conference Call Participants Jonathan Chang - SVB Leerink Marc Frahm - Cowen & Company Operator Good day, ladies and gentlemen, and welcome to the Revolution Medicines Fourth Quarter and Ful ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39219 Registrant's telephone number, including area code: (650) 481-6801 Securities registered pursuant to Section 12(b) of the Act: ...

On Target to Outsmart Cancer TM A N U A RY 1 , 2 0 2 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain existing collaborations, including with Sanofi, and est ...

Translating Frontier | --- | --- | --- | |---------------------|-------|-------| | | | | | Oncology Targets to | | | © 2021 Revolution Medicines Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availabili ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Peg Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance & Principal Accounting Officer Steve Kelsey - President of R&D Conference Call Participants Michael Schmidt - Guggenheim Jonathan Chang - SVB Leerink Eric Joseph - JPMorgan Marc Frahm - Cowen & Company Chris Shibutani - Goldman Sachs Benjamin Burnett ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2021 Results Conference Call August 11, 2021 4:30 PM ET Company Participants Peg Horn - Chief Operating Officer Dr. Mark Goldsmith - Chairman and Chief Executive Officer Dr. Steve Kelsey - President Research and Development Jack Anders - Senior Vice President of Finance and Principal Accounting Officer Conference Call Participants Chris Shibutani - Goldman Sachs Marc Frahm - Cowen Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Faisal Khurshid - SVB Leerink Op ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 700 Saginaw Drive Redwood City, CA 94063 Delaware 47-2029180 (I.R.S. Employer Identification No.) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quar ...